It seems those who know better are thinking differently to the retail day-traders who panicked!
I like this bit that reflects what I had anticipated to be the case, that further analysis of data (good or average results in subgroups) will shine light on how application/technique can be improved:
"The [subgroup] data allows us to more specifically address certain meaningful patient populations and maximize the chance of a benefit for those patient groups. "
... which may answer your question @ML173.
Ann: EOC Pharma confirms plans to advance Efti in China for MBC, page-3
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
29.5¢ |
Change
0.005(1.72%) |
Mkt cap ! $428.5M | |||
| Open | High | Low | Value | Volume |
| 28.5¢ | 30.5¢ | 28.5¢ | $469.8K | 1.579M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 297652 | 29.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 30.0¢ | 7500 | 2 |
View Market Depth
| Last trade - 16.10pm 19/07/2024 (20 minute delay) ? |
| IMM (ASX) Chart |